markers and elevated liver function tests, the most likely histological diagnosis is fatty liver (liver steatosis), with or without fibrosis. [5] [6] [7] [8] Nonalcoholic fatty liver disease has been recognized as one of the leading causes of chronic liver disease. It is intimately related to insulin resistance and may evolve into steatohepatitis. Fibrosis stage is recognized as the most objective indicator of liver damage and is the best prognostic marker for morbidity and mortality in liver disease. [9] [10] [11] [12] Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor for the fibrinolytic system, with levels mainly dependent on the metabolic status. 13 PAI-1 is considered a good predictor of type 2 diabetes, 14 and its increased plasma levels are indeed generally associated with increased risk for thrombosis, atherosclerosis, or fatal cardiovascular events. 15, 16 Many cells/tissues (endothelial, hepatocytes, monocyte, smooth muscle cells, adipose tissue, and so on) have the capability to synthesize PAI-1, whose gene expression is inducible by many components of MS. Additionally, genetic variation at a polymorphic M etabolic syndrome (MS) has assumed great importance in recent years, after the identification of several factors associated with it, and has established itself as a health care crisis of epidemic proportion. 1 The key components responsible for MS include central obesity, insulin resistance, dyslipidemia, and hypertension, in addition to chronic inflammation, procoagulation state, and impaired fibrinolysis. 2, 3 All of these features are risk factors for atherosclerosis, and moreover, MS constitutes a significant risk for coronary heart disease. 4 Successive findings have clearly shown that, in patients with features of MS with negative hepatitis Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (β = .455) and HDL-cholesterol (β = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content. Keywords: fatty liver; insulin resistance; liver fibrosis; metabolic syndrome; PAI-1 locus of the PAI-1 gene is associated with differences in plasma PAI-1 levels. 3, 13, [16] [17] [18] Cigolini et al 19 and, more recently, Alessi et al 20 observed a highly significant association between plasma PAI-1 levels and the degree of liver steatosis. Thus, liver steatosis or the mechanism that leads to liver steatosis may be involved in PAI-1 synthesis in insulin resistance syndrome. In addition, overexpression of PAI-1 may aggravate liver fat storage. 3 These observations prompted us to study the plasma PAI-1 levels and their relations with well-known risk factors for MS, especially nonalcoholic fatty liver.
Materials and Methods

Patients
One hundred seventy consecutive patients who had 1 or more well-known risk factors for MS were studied according to the Adult Treatment Panel III of the National Cholesterol Education Program. 21 All of them were receiving treatment as outpatients attending the Endocrine Division of Hospital Durand in Buenos Aires. At the initial stages of the study, all the patients were subjected to a liver ultrasound scan, and blood samples were taken for further evaluation. Those with chronically elevated transaminase levels (and who gave their written consent) underwent a liver biopsy (n = 54).
Conforming with the exclusion criteria, individuals not included in the study were those who refused treatment, were pregnant or breast-feeding, were younger than 18 years, had hepatitis B or chronic C, suffered from autoimmune hepatitis or genetic hemochromatosis, had a history of malignant disease or decompensated cirrhosis, or had serum creatinine > 2 mg/dL or bleeding disorders. Furthermore, patients taking anabolic treatment, oral contraceptives, steatogenic drugs; consuming more than 20 g/day of alcohol; or using illicit drugs were also excluded, as were those who had primary HIV infection or ongoing opportunistic infections. All patients gave their written informed consent before enrollment in the study, and the Hospital Ethics Committee approved the protocol.
Clinical Data
The patients were asked about their family history of diabetes, dyslipidemia, and high blood pressure. The anthropometric assessment included measurement of weight, height, and waist circumference. Body mass index (BMI) was calculated by using the standard formula: weight (kg)/height (m 2 ). Overweight was defined as BMI between 25 and 29.9 and obesity as BMI ≥ 30. The cutoff for waist circumference was >88 cm in women and >102 cm in men.
Blood Samples
Samples were obtained by clean venipuncture without stasis after overnight fasting of 12 hours and 15 minutes of supine rest and were collected into plastic tubes containing sodium citrate (ratio 9:1). After double centrifugation at 2500g for 15 minutes, plateletpoor plasma was immediately stored at −40°C. Blood was collected into tubes, allowed to clot at 37°C, and then centrifuged at 1500g to be used for sera preparation. Samples were kept frozen at −40°C until use.
Laboratory Studies
Blood fasting glucose was assayed by glucose-oxidase methods (Roche, Nutley, NJ). Serum insulin was measured by microparticle enzyme immunoassay (Abbott, Abbott Park, IL), and insulin resistance was estimated by homeostasis model assessment (HOMA). The HOMA model (insulin resistance = fasting insulin [μU/mL] × fasting glucose [mmol/L] / 22.5) may provide a useful additional tool to assess risk of diabetes. The cutoff for insulin resistance was HOMA > 2.21 (our own data). The serum levels of the following components were measured by standard techniques (Roche): triglycerides (TG), high-density lipoprotein cholesterol (HDL cholesterol), low-density lipoprotein cholesterol (following pretreatment of the sample), alanine aminotransferase, uric acid, alkaline phosphatase, aspartate aminotransferase (AST), and γ-glutamyltransferase. Plasma levels of plasminogen activator inhibitor-1 (PAI-1) were evaluated by chromogenic assay (Diagnostica Stago, France). All sera and plasma samples were thawed only once in a water bath at 37°C for 15 minutes before testing.
Ultrasound Scan of the Liver
As an initial step of examination, all patients underwent a liver ultrasound scan. A single trained operator performed liver ultrasonography scanning of all the participants. Hepatic steatosis was diagnosed by characteristic echo patterns according to the conventional criteria. Subjects were classified as having liver steatosis when the echogenicity of the liver was higher than that of the kidneys (bright liver), whereas those with very similar echogenicity were classified as subjects without liver steatosis. Steatosis was graded by a 4-grade point scale: grade 0, without steatosis; grade 1, steatosis involving <33% of the liver; grade 2, 33%-66%; grade 3, >66%. Repeated measurements in the same subjects gave coefficients of variation < 1%.
Liver Histology
With the intention of evaluating liver histology, those patients with chronically elevated transaminase levels were subjected to a liver biopsy. The cutoffs for liver enzymes were based on the upper limits of normal values of our laboratory: alanine aminotransferase being 10-42 IU/L and AST being 10-38 IU/L. Liver specimens were read by a single liver pathologist who was unaware of the patients' details. All biopsy samples (n = 54) were a minimum of 15 mm in length and had an appropriate number of portal tracts to make a reliable evaluation of histological features and diagnosis. Histological features were interpreted according to the scheme outlined by Brunt et al. In short, steatosis was graded by a 3-grade point scale: grade 1, steatosis involving <33% of hepatocytes; grade 2, 33%-66%; and grade 3, >66%. Fibrosis was staged by a 4-stage point scale: stage 0, no fibrosis; stage 1, zone 3 perisinusoidal/ perivenular fibrosis; stage 2, zone 3 and periportal fibrosis; stage 4, septal/bridging fibrosis and/or cirrhosis.
Statistical Analysis
Statistical analysis was performed by using SPSS for Windows (SPSS, Chicago, IL). As data were not normally distributed, they were given as median and quartiles (25%-75%), or percentages. The Spearman test was used to correlate variables. A stepwise multiple regression analysis was performed to test the joint effect of different univariate predictors added to the model for P < .05.
Results
The study group consisted of 170 outpatients, 129 women and 41 men, with a median age of 45 years (quartiles: 29-55). Table 1 shows median and quartiles, or percentages, of all studied variables in patients who had risk factors for MS. Fifty percent of all patients had confirmed diagnosis of MS. As shown in Table 2 , plasma PAI-1 levels showed a positive significant correlation with BMI, grade of steatosis by ultrasound scan, HOMA, insulin, waist circumference, and triglycerides and a negative significant correlation with HDL cholesterol. In a stepwise multivariate analysis, only BMI and HDL cholesterol remained predictors of PAI-1 levels. As a consequence of these results, we decided to analyze patients with normal weight (BMI < 25 kg/[m 2 ]; n = 16). In these patients, PAI-1 levels had a significant correlation only with HOMA (r = 0.559; P = .024) and insulin levels (r = 0.556; P = .025). Table 3 shows correlations in 54 patients with liver biopsy between liver fibrosis or the degree of liver steatosis with the studied variables. It is essential to state here that a positive and significant correlation PAI-1 and Nonalcoholic Fatty Liver Disease / Larrañaga et al 321 was observed between HOMA or insulin levels and liver fibrosis.
Discussion
We showed that, although there was a significant correlation between plasma PAI-1 levels and liver fat content, plasma PAI-1 levels were more strongly conditioned to total body fat content in patients with features of MS than to the liver fat content. It is interesting that, in lean patients, PAI-1 levels were associated with insulin resistance status but had no direct association with liver fat content. However, in patients who underwent liver biopsy, hepatic fibrosis kept a close association with insulin resistance status. Undoubtedly, obesity represents a serious problem in industrialized countries. Bad food habits in addition to sedentary lifestyle are highly conducive factors in the development of this condition. Thus, obesity has a significant role in the mental and physical health of affected people. Consistent with this finding, the most frequently manifested debilitating factor is cardiovascular disease, mediated in most cases by type 2 diabetes. 4, 16, 22 Our cohort of patients had a considerably high BMI: all except 16 presented some degree of obesity.
The presence of fatty liver in patients with type 2 diabetes and obesity has long been reported as an incidental pathological finding of scarce or no clinical significance. Nonalcoholic fatty liver disease has recently been recognized to be the leading cause of chronic liver disease, a potentially progressive disease that may cause cirrhosis and liver-related death. [8] [9] [10] [11] [12] Fatty liver represents the liver component of MS with a clear relationship with insulin resistance. [5] [6] [7] As expected from the results of this study, 70.9% of our patients had some kind of fatty liver as revealed by ultrasound scan. Moreover, almost 50% of all patients had the highest degree of fatty liver. Today, it is accepted that fat accumulation in the liver represents an adaptable answer of the liver to the presence of insulin resistance.
PAI-1 is the primary inhibitor in the fibrinolytic system. In addition to this finding, PAI-1 plays a role in many other pathophysiological processes such as atherosclerosis, obesity, angiogenesis, chronic stress, and insulin resistance, which turn PAI-1 into a very attractive point of study. 13, [23] [24] [25] In the present study, PAI-1 levels significantly correlated with many features of MS, including liver fat content detected by an ultrasound scan as expected, but contrarily, the body fat content (expressed as BMI) represented the strongest predictor of PAI-1 levels. This fact forced us to speculate that, although PAI-1 gene expression may be inducible by different metabolic factors and in different cells, in the presence of obesity and extreme obesity, plasma levels of PAI-1 were mainly conditioned by the whole body fat content. As a consequence of this consideration, we studied lean subjects separately. In this population, plasma PAI-1 levels had a strong relationship with insulin resistance status 322 Clinical and Applied Thrombosis/Hemostasis / Vol. 14, No. 3, July 2008 without a clear relationship with liver fat content. The number of lean subjects in our work may have been too small to exhibit any type of relation. In fact, raised levels of PAI-1 could not be disregarded as another contributory factor to liver steatosis. Certainly, recent works have indicated that PAI-1 may have functions, namely, in lipid metabolism. 20, 24 Those works support the hypothesis that PAI-1 is involved in the development of hepatic steatosis. Bergheim et al 26 suggested a novel pathway in a mouse model of steatosis caused by acute and chronic alcohol exposure, involving the induction of PAI-1 expression by means of a tumor necrosis factor-α-dependent pathway. PAI-1 -/mice were protected against lipid accumulation in the liver owing to ethanol. Fat accumulation in the liver and skeletal muscle were associated with severe insulin resistance and signaling defects of insulin. 27, 28 Currently, reduced insulin resistance status has improved liver fat accumulation 9, 10, 24, 26, 29, 30 and has reduced plasma PAI-1 levels. 31, 32 Drugs frequently used for the treatment of metabolic syndrome, such as thiazolidinediones and metformin, also have a concomitant beneficial effect on impaired fibrinolysis-reducing PAI-1 levels; and may thereby reduce the cardiovascular risk in those patients.
It is well known that the degree of hepatic fibrosis is recognized as the best prognostic marker of mortality and morbidity in liver disease. [10] [11] [12] 29, 33 Therefore, we investigated the relationship between the degree of fibrosis (by liver biopsy) and the studied variables. As PAI-1 has been involved in processes such as cell migration and tissue remodeling, we principally considered the investigation of the possible role of PAI-1 and liver fibrosis. As expected, the liver fibrosis manifested a strong association with insulin resistance status but not directly with PAI-1 level. Although the insulin resistance status has been recognized as one of the principal pathophysiological conditions for the development of liver fibrosis, the raised level of PAI-1 could not be overlooked as another contributing factor to liver fibrosis (or to liver steatosis as mentioned). 26 Unfortunately, we studied too few patients with insulin resistance and liver biopsy to be able to determine this complex puzzle.
In conclusion, our results further confirm that most of the patients with features of MS were obese and had evidence of fatty liver disease. The wholebody fat content mainly conditioned plasma PAI-1 levels. Hepatic fibrosis was in close relationship with insulin resistance status, with no clear relation with plasma PAI-1 levels.
